Dynamics, Pharmacokinetics, and Dosimetry of First-in-Human [⁶⁸Ga]Ga-OncoACP3-DOTA PET in Patients with Prostate Cancer.

Ga]Ga-OncoACP3-DOTA demonstrated favorable pharmacokinetics with increasing tumor uptake and tumor-to-background ratios at later time points, suggesting potential benefits for delayed imaging, especially with high-sensitive PET systems or radiolabeling with isotopes with longer half-lives. The dosimetry profile was favorable, with a lower effective dose compared with many prostate-specific membrane antigen-targeted radiopharmaceuticals and negligible salivary gland uptake, potentially reducing side effects during radiopharmaceutical therapy. Future studies are warranted to evaluate its clinical value.